

Luca Gianni

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3531751/publications.pdf>

Version: 2024-02-01

154
papers

36,674
citations

14614

66
h-index

8835

145
g-index

161
all docs

161
docs citations

161
times ranked

31647
citing authors

#	ARTICLE	IF	CITATIONS
1	Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer. <i>New England Journal of Medicine</i> , 2005, 353, 1659-1672.	13.9	4,601
2	Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. <i>Lancet, The</i> , 2014, 384, 164-172.	6.3	3,224
3	Anthracyclines: Molecular Advances and Pharmacologic Developments in Antitumor Activity and Cardiotoxicity. <i>Pharmacological Reviews</i> , 2004, 56, 185-229.	7.1	3,060
4	Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer. <i>New England Journal of Medicine</i> , 2012, 367, 1783-1791.	13.9	3,020
5	Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease. <i>Nature Reviews Clinical Oncology</i> , 2016, 13, 674-690.	12.5	1,938
6	Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. <i>Lancet Oncology, The</i> , 2012, 13, 25-32.	5.1	1,879
7	Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort. <i>Lancet, The</i> , 2010, 375, 377-384.	6.3	1,061
8	11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial. <i>Lancet, The</i> , 2017, 389, 1195-1205.	6.3	770
9	Treatment of HER2-positive breast cancer: current status and future perspectives. <i>Nature Reviews Clinical Oncology</i> , 2012, 9, 16-32.	12.5	735
10	Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials. <i>Lancet Oncology, The</i> , 2018, 19, 27-39.	5.1	717
11	Triple-negative breast cancer: disease entity or title of convenience?. <i>Nature Reviews Clinical Oncology</i> , 2010, 7, 683-692.	12.5	708
12	HER2-positive breast cancer. <i>Lancet, The</i> , 2017, 389, 2415-2429.	6.3	655
13	Triple-Negative Breast Cancer: An Unmet Medical Need. <i>Oncologist</i> , 2011, 16, 1-11.	1.9	636
14	5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial. <i>Lancet Oncology, The</i> , 2016, 17, 791-800.	5.1	623
15	Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer. <i>New England Journal of Medicine</i> , 2021, 384, 1529-1541.	13.9	601
16	Phase II Trial of Pertuzumab and Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer That Progressed During Prior Trastuzumab Therapy. <i>Journal of Clinical Oncology</i> , 2010, 28, 1138-1144.	0.8	593
17	Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial. <i>Lancet Oncology, The</i> , 2011, 12, 236-244.	5.1	575
18	Gene Expression Profiles in Paraffin-Embedded Core Biopsy Tissue Predict Response to Chemotherapy in Women With Locally Advanced Breast Cancer. <i>Journal of Clinical Oncology</i> , 2005, 23, 7265-7277.	0.8	531

#	ARTICLE	IF	CITATIONS
19	2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial. <i>Lancet, The</i> , 2013, 382, 1021-1028.	6.3	447
20	Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial. <i>Lancet Oncology, The</i> , 2017, 18, 732-742.	5.1	447
21	Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial. <i>Lancet Oncology, The</i> , 2014, 15, 580-591.	5.1	434
22	Treatment landscape of triple-negative breast cancer – expanded options, evolving needs. <i>Nature Reviews Clinical Oncology</i> , 2022, 19, 91-113.	12.5	414
23	Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort. <i>Lancet Oncology, The</i> , 2014, 15, 640-647.	5.1	406
24	Preoperative Therapy in Invasive Breast Cancer: Pathologic Assessment and Systemic Therapy Issues in Operable Disease. <i>Journal of Clinical Oncology</i> , 2008, 26, 814-819.	0.8	352
25	International Expert Panel on the Use of Primary (Preoperative) Systemic Treatment of Operable Breast Cancer: Review and Recommendations. <i>Journal of Clinical Oncology</i> , 2003, 21, 2600-2608.	0.8	322
26	AVEREL: A Randomized Phase III Trial Evaluating Bevacizumab in Combination With Docetaxel and Trastuzumab As First-Line Therapy for HER2-Positive Locally Recurrent/Metastatic Breast Cancer. <i>Journal of Clinical Oncology</i> , 2013, 31, 1719-1725.	0.8	247
27	The immune system and response to HER2-targeted treatment in breast cancer. <i>Lancet Oncology, The</i> , 2014, 15, e58-e68.	5.1	244
28	Oxidative destruction of erythrocyte ghost membranes catalyzed by the doxorubicin-iron complex. <i>Biochemistry</i> , 1982, 21, 1707-1713.	1.2	232
29	30 years' follow up of randomised studies of adjuvant CMF in operable breast cancer: cohort study. <i>BMJ: British Medical Journal</i> , 2005, 330, 217.	2.4	224
30	Pertuzumab Monotherapy After Trastuzumab-Based Treatment and Subsequent Reintroduction of Trastuzumab: Activity and Tolerability in Patients With Advanced Human Epidermal Growth Factor Receptor 2 – Positive Breast Cancer. <i>Journal of Clinical Oncology</i> , 2012, 30, 1594-1600.	0.8	221
31	Open-Label, Phase II, Multicenter, Randomized Study of the Efficacy and Safety of Two Dose Levels of Pertuzumab, a Human Epidermal Growth Factor Receptor 2 Dimerization Inhibitor, in Patients With Human Epidermal Growth Factor Receptor 2 – Negative Metastatic Breast Cancer. <i>Journal of Clinical Oncology</i> , 2010, 28, 1131-1137.	0.8	214
32	Trastuzumab-Associated Cardiac Events at 8 Years of Median Follow-Up in the Herceptin Adjuvant Trial (BIG 1-01). <i>Journal of Clinical Oncology</i> , 2014, 32, 2159-2165.	0.8	207
33	Phase III Trial Evaluating the Addition of Paclitaxel to Doxorubicin Followed by Cyclophosphamide, Methotrexate, and Fluorouracil, As Adjuvant or Primary Systemic Therapy: European Cooperative Trial in Operable Breast Cancer. <i>Journal of Clinical Oncology</i> , 2009, 27, 2474-2481.	0.8	194
34	Molecular Anatomy of Breast Cancer Stroma and Its Prognostic Value in Estrogen Receptor – Positive and – Negative Cancers. <i>Journal of Clinical Oncology</i> , 2010, 28, 4316-4323.	0.8	193
35	Research-Based PAM50 Subtype Predictor Identifies Higher Responses and Improved Survival Outcomes in HER2-Positive Breast Cancer in the NOAH Study. <i>Clinical Cancer Research</i> , 2014, 20, 511-521.	3.2	191
36	Adjuvant vemurafenib in resected, BRAFV600 mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial. <i>Lancet Oncology, The</i> , 2018, 19, 510-520.	5.1	183

#	ARTICLE	IF	CITATIONS
37	Safety and efficacy of preoperative or postoperative chemotherapy for resectable pancreatic adenocarcinoma (PACT-15): a randomised, open-label, phase 2â€“3 trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2018, 3, 413-423.	3.7	180
38	Long-Term Cardiac Sequelae in Operable Breast Cancer Patients Given Adjuvant Chemotherapy With or Without Doxorubicin and Breast Irradiation. <i>Journal of Clinical Oncology</i> , 2001, 19, 37-43.	0.8	170
39	Oxidative destruction of DNA by the adriamycin-iron complex. <i>Biochemistry</i> , 1984, 23, 928-936.	1.2	168
40	Trabectedin for Women With Ovarian Carcinoma After Treatment With Platinum and Taxanes Fails. <i>Journal of Clinical Oncology</i> , 2005, 23, 1867-1874.	0.8	163
41	Response to Cyclophosphamide, Methotrexate, and Fluorouracil in Lymph Nodeâ€“Positive Breast Cancer According to HER2 Overexpression and Other Tumor Biologic Variables. <i>Journal of Clinical Oncology</i> , 2001, 19, 329-335.	0.8	147
42	Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13â€“864 women in seven randomised trials. <i>Lancet Oncology</i> , The, 2021, 22, 1139-1150.	5.1	147
43	Feasibility and Tolerability of Sequential Doxorubicin/Paclitaxel Followed by Cyclophosphamide, Methotrexate, and Fluorouracil and Its Effects on Tumor Response as Preoperative Therapy. <i>Clinical Cancer Research</i> , 2005, 11, 8715-8721.	3.2	146
44	Phase I trial of oral mTOR inhibitor everolimus in combination with trastuzumab and vinorelbine in pre-treated patients with HER2-overexpressing metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2011, 125, 447-455.	1.1	142
45	Symptomatic and neurophysiological responses of paclitaxel- or cisplatin-induced neuropathy to oral acetyl-l-carnitine. <i>European Journal of Cancer</i> , 2005, 41, 1746-1750.	1.3	138
46	Hydroxyl radical production and DNA damage induced by anthracycline-iron complex. <i>FEBS Letters</i> , 1984, 172, 226-230.	1.3	136
47	Mechanism-Based Pharmacokinetic Model for Paclitaxel. <i>Journal of Clinical Oncology</i> , 2001, 19, 4065-4073.	0.8	133
48	Current Status and Future Perspectives on Neoadjuvant Therapy in Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1818-1831.	0.5	133
49	Neoadjuvant treatment with trastuzumab and pertuzumab plus palbociclib and fulvestrant in HER2-positive, ER-positive breast cancer (NA-PHER2): an exploratory, open-label, phase 2 study. <i>Lancet Oncology</i> , The, 2018, 19, 249-256.	5.1	130
50	Comparing Neoadjuvant Nab-paclitaxel vs Paclitaxel Both Followed by Anthracycline Regimens in Women With <i>ERBB2/HER2</i>-Negative Breast Cancerâ€“The Evaluating Treatment With Neoadjuvant Abraxane (ETNA) Trial. <i>JAMA Oncology</i> , 2018, 4, 302.	3.4	115
51	Inhibition of proliferation and induction of apoptosis in breast cancer cells by the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor ZD1839 (â€“Iressaâ€“™) is independent of EGFR expression level. <i>Journal of Cellular Physiology</i> , 2004, 198, 259-268.	2.0	108
52	Anthracycline cardiotoxicity in breast cancer patients: synergism with trastuzumab and taxanes. <i>Cardiovascular Toxicology</i> , 2007, 7, 67-71.	1.1	107
53	Clinical Relevance of Different Sequencing of Doxorubicin and Cyclophosphamide, Methotrexate, and Fluorouracil in Operable Breast Cancer. <i>Journal of Clinical Oncology</i> , 2004, 22, 1614-1620.	0.8	106
54	Bevacizumab Prevents Brain Metastases Formation in Lung Adenocarcinoma. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 702-710.	1.9	103

#	ARTICLE	IF	CITATIONS
55	Phase II multicenter, uncontrolled trial of sorafenib in patients with metastatic breast cancer. <i>Anti-Cancer Drugs</i> , 2009, 20, 616-624.	0.7	102
56	Results from a phase 2 study of enzalutamide (ENZA), an androgen receptor (AR) inhibitor, in advanced AR+ triple-negative breast cancer (TNBC).. <i>Journal of Clinical Oncology</i> , 2015, 33, 1003-1003.	0.8	101
57	Utility of Serum HER2 Extracellular Domain Assessment in Clinical Decision Making: Pooled Analysis of Four Trials of Trastuzumab in Metastatic Breast Cancer. <i>Journal of Clinical Oncology</i> , 2009, 27, 1685-1693.	0.8	100
58	Defective One- or Two-electron Reduction of the Anticancer Anthracycline Epirubicin in Human Heart. <i>Journal of Biological Chemistry</i> , 2006, 281, 10990-11001.	1.6	88
59	Biomarker analysis of the NeoSphere study: pertuzumab, trastuzumab, and docetaxel versus trastuzumab plus docetaxel, pertuzumab plus trastuzumab, or pertuzumab plus docetaxel for the neoadjuvant treatment of HER2-positive breast cancer. <i>Breast Cancer Research</i> , 2017, 19, 16.	2.2	83
60	Role of Anthracyclines in the Treatment of Early Breast Cancer. <i>Journal of Clinical Oncology</i> , 2009, 27, 4798-4808.	0.8	82
61	Extracellular Matrix/Integrin Signaling Promotes Resistance to Combined Inhibition of HER2 and PI3K in HER2+ Breast Cancer. <i>Cancer Research</i> , 2017, 77, 3280-3292.	0.4	76
62	Trastuzumab as adjuvant systemic therapy for HER2-positive breast cancer. <i>Nature Clinical Practice Oncology</i> , 2009, 6, 93-104.	4.3	75
63	Phase IIa Trial of Trastuzumab Emtansine With Pertuzumab for Patients With Human Epidermal Growth Factor Receptor 2â€“Positive, Locally Advanced, or Metastatic Breast Cancer. <i>Journal of Clinical Oncology</i> , 2014, 32, 1437-1444.	0.8	72
64	Primary and salvage chemotherapy in advanced Hodgkin's disease: The Milan Cancer Institute experience. <i>Annals of Oncology</i> , 1991, 2, 9-16.	0.6	68
65	Targeting TRAIL Agonistic Receptors for Cancer Therapy. <i>Clinical Cancer Research</i> , 2007, 13, 2313-2317.	3.2	67
66	Feasibility and Cardiac Safety of Trastuzumab Emtansine After Anthracycline-Based Chemotherapy As (neo)Adjuvant Therapy for Human Epidermal Growth Factor Receptor 2â€“Positive Early-Stage Breast Cancer. <i>Journal of Clinical Oncology</i> , 2015, 33, 1136-1142.	0.8	67
67	Paclitaxel and Docetaxel Stimulation of Doxorubicinol Formation in the Human Heart: Implications for Cardiotoxicity of Doxorubicin-Taxane Chemotherapies. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2006, 318, 424-433.	1.3	63
68	International Expert Consensus on Primary Systemic Therapy in the Management of Early Breast Cancer: Highlights of the Fourth Symposium on Primary Systemic Therapy in the Management of Operable Breast Cancer, Cremona, Italy (2010). <i>Journal of the National Cancer Institute Monographs</i> , 2011, 2011, 147-151.	0.9	61
69	Differences in O2 reduction by the iron complexes of adriamycin and daunomycin: the importance of the sidechain hydroxyl group. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 1986, 884, 326-336.	1.1	58
70	Prognostic and Therapeutic Implications of Distinct Kinase Expression Patterns in Different Subtypes of Breast Cancer. <i>Cancer Research</i> , 2010, 70, 8852-8862.	0.4	58
71	Subtype-Specific Metagene-Based Prediction of Outcome after Neoadjuvant and Adjuvant Treatment in Breast Cancer. <i>Clinical Cancer Research</i> , 2016, 22, 337-345.	3.2	58
72	Inter-relationships of paclitaxel disposition, infusion duration and Cremophor EL kinetics in cancer patients. <i>Anti-Cancer Drugs</i> , 2000, 11, 331-337.	0.7	52

#	ARTICLE	IF	CITATIONS
73	Nab-paclitaxel plus gemcitabine with or without capecitabine and cisplatin in metastatic pancreatic adenocarcinoma (PACT-19): a randomised phase 2 trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2018, 3, 691-697.	3.7	50
74	A randomised phase 2 trial of nab-paclitaxel plus gemcitabine with or without capecitabine and cisplatin in locally advanced or borderline resectable pancreatic adenocarcinoma. <i>European Journal of Cancer</i> , 2018, 102, 95-102.	1.3	50
75	Relationship between HER2 expression and efficacy with first-line trastuzumab emtansine compared with trastuzumab plus docetaxel in TDM4450g: a randomized phase II study of patients with previously untreated HER2-positive metastatic breast cancer. <i>Breast Cancer Research</i> , 2014, 16, R50.	2.2	49
76	Phase IB Study of the mTOR Inhibitor Ridaforolimus With Capecitabine. <i>Journal of Clinical Oncology</i> , 2010, 28, 4554-4561.	0.8	47
77	Future options with trastuzumab for primary systemic and adjuvant therapy. <i>Seminars in Oncology</i> , 2004, 31, 51-57.	0.8	45
78	Hallmarks of triple negative breast cancer emerging at last?. <i>Cell Research</i> , 2014, 24, 904-905.	5.7	45
79	Proliferation and estrogen signaling can distinguish patients at risk for early versus late relapse among estrogen receptor positive breast cancers. <i>Breast Cancer Research</i> , 2013, 15, R86.	2.2	44
80	Pilot trial of trastuzumab starting with or after the doxorubicin component of a doxorubicin plus paclitaxel regimen for women with HER2-positive advanced breast cancer. <i>Clinical Cancer Research</i> , 2003, 9, 5944-51.	3.2	42
81	Phase I clinical and pharmacological evaluation of the multi-tyrosine kinase inhibitor SU006668 by chronic oral dosing. <i>European Journal of Cancer</i> , 2006, 42, 171-178.	1.3	39
82	Magnitude of Trastuzumab Benefit in Patients With HER2-Positive, Invasive Lobular Breast Carcinoma: Results From the HERA Trial. <i>Journal of Clinical Oncology</i> , 2013, 31, 1954-1960.	0.8	39
83	Clinical and Pharmacologic Study of the Epirubicin and Paclitaxel Combination in Women With Metastatic Breast Cancer. <i>Journal of Clinical Oncology</i> , 2001, 19, 2222-2231.	0.8	38
84	Updated efficacy, safety, & PD-L1 status of patients with HR+, HER2- metastatic breast cancer administered abemaciclib plus pembrolizumab.. <i>Journal of Clinical Oncology</i> , 2018, 36, 1059-1059.	0.8	38
85	Clinical and pharmacokinetic study of sunitinib and docetaxel in women with advanced breast cancer. <i>Breast</i> , 2012, 21, 507-513.	0.9	36
86	Defective Taxane Stimulation of Epirubicinol Formation in the Human Heart: Insight into the Cardiac Tolerability of Epirubicin-Taxane Chemotherapies. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2007, 320, 790-800.	1.3	35
87	Trastuzumab Emtansine Plus Pertuzumab Versus Taxane Plus Trastuzumab Plus Pertuzumab After Anthracycline for High-Risk Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer: The Phase III KAITLIN Study. <i>Journal of Clinical Oncology</i> , 2022, 40, 438-448.	0.8	35
88	Long-term results of a combination of paclitaxel, cisplatin and gemcitabine for salvage therapy in male germ-cell tumours. <i>BJU International</i> , 2009, 104, 340-346.	1.3	34
89	Primary results from EMILIA, a phase III study of trastuzumab emtansine (T-DM1) versus capecitabine (X) and lapatinib (L) in HER2-positive locally advanced or metastatic breast cancer (MBC) previously treated with trastuzumab (T) and a taxane.. <i>Journal of Clinical Oncology</i> , 2012, 30, LBA1-LBA1.	0.8	34
90	Phase III, randomized, double-blind, placebo-controlled multicenter trial of daily everolimus plus weekly trastuzumab and vinorelbine in trastuzumab-resistant, advanced breast cancer (BOLERO-3).. <i>Journal of Clinical Oncology</i> , 2013, 31, 505-505.	0.8	34

#	ARTICLE	IF	CITATIONS
91	Phase 1B trial of Nab-paclitaxel plus gemcitabine, capecitabine, and cisplatin (PAXG regimen) in patients with unresectable or borderline resectable pancreatic adenocarcinoma. <i>British Journal of Cancer</i> , 2016, 115, 290-296.	2.9	29
92	Primary results from EMILIA, a phase III study of trastuzumab emtansine (T-DM1) versus capecitabine (X) and lapatinib (L) in HER2-positive locally advanced or metastatic breast cancer (MBC) previously treated with trastuzumab (T) and a taxane.. <i>Journal of Clinical Oncology</i> , 2012, 30, LBA1-LBA1.	0.8	29
93	Clinical Development Strategies and Outcomes in First-in-Human Trials of Monoclonal Antibodies. <i>Journal of Clinical Oncology</i> , 2015, 33, 2158-2165.	0.8	27
94	Drug interactions of paclitaxel and docetaxel and their relevance for the design of combination therapy. <i>Investigational New Drugs</i> , 2001, 19, 179-196.	1.2	26
95	Anthracycline Cardiotoxicity. <i>Topics in Current Chemistry</i> , 2007, 283, 21-44.	4.0	26
96	Ixabepilone and the Narrow Path to Developing New Cytotoxic Drugs. <i>Journal of Clinical Oncology</i> , 2007, 25, 3389-3391.	0.8	25
97	Treatment sequence with either irinotecan/cetuximab followed by FOLFOX-4 or the reverse strategy in metastatic colorectal cancer patients progressing after first-line FOLFIRI/bevacizumab: An Italian Group for the Study of Gastrointestinal Cancer phase III, randomised trial comparing two sequences of therapy in colorectal metastatic patients. <i>European Journal of Cancer</i> , 2017, 83, 106-115.	1.3	25
98	Sacituzumab govitecan as second-line treatment for metastatic triple-negative breast cancer—phase 3 ASCENT study subanalysis. <i>Npj Breast Cancer</i> , 2022, 8, .	2.3	25
99	Adjuvant and neoadjuvant treatment of breast cancer. <i>Seminars in Oncology</i> , 2001, 28, 13-29.	0.8	22
100	The Future of Targeted Therapy: Combining Novel Agents. <i>Oncology</i> , 2002, 63, 47-56.	0.9	22
101	Technology Insight: emerging techniques to predict response to preoperative chemotherapy in breast cancer. <i>Nature Clinical Practice Oncology</i> , 2004, 1, 44-50.	4.3	22
102	Cardiotoxic effects of anthracycline—taxane combinations. <i>Expert Opinion on Drug Safety</i> , 2003, 2, 59-71.	1.0	21
103	The “Other” Signaling of Trastuzumab: Antibodies Are Immunocompetent Drugs. <i>Journal of Clinical Oncology</i> , 2008, 26, 1778-1780.	0.8	20
104	Phase I clinical and pharmacokinetic study of ombrabulin (AVE8062) combined with cisplatin/docetaxel or carboplatin/paclitaxel in patients with advanced solid tumors. <i>Investigational New Drugs</i> , 2014, 32, 1188-1196.	1.2	20
105	Five-year analysis of the phase II NeoSphere trial evaluating four cycles of neoadjuvant docetaxel (D) and/or trastuzumab (T) and/or pertuzumab (P).. <i>Journal of Clinical Oncology</i> , 2015, 33, 505-505.	0.8	19
106	Strategies for clinical development of monoclonal antibodies beyond first-in-human trials: tested doses and rationale for dose selection. <i>British Journal of Cancer</i> , 2018, 118, 679-697.	2.9	17
107	Effects of neoadjuvant trastuzumab, pertuzumab and palbociclib on Ki67 in HER2 and ER-positive breast cancer. <i>Npj Breast Cancer</i> , 2022, 8, 1.	2.3	17
108	Monoclonal antibodies against doxorubicin. <i>International Journal of Cancer</i> , 1988, 42, 798-802.	2.3	15

#	ARTICLE	IF	CITATIONS
109	Anthracyclines and Early Breast Cancer: The End of an Era?. <i>Journal of Clinical Oncology</i> , 2009, 27, 1155-1157.	0.8	15
110	Phase I clinical and pharmacokinetic study of trabectedin and cisplatin given every three weeks in patients with advanced solid tumors. <i>Investigational New Drugs</i> , 2013, 31, 1236-1243.	1.2	15
111	Risk-based decision-making in the treatment of HER2-positive early breast cancer: Recommendations based on the current state of knowledge. <i>Cancer Treatment Reviews</i> , 2021, 99, 102229.	3.4	15
112	ecancermedalscience. <i>Ecancermedalscience</i> , 2014, 8, 433.	0.6	12
113	Phase I study of tomuzotuximab, a glycoengineered therapeutic antibody against the epidermal growth factor receptor, in patients with advanced carcinomas. <i>ESMO Open</i> , 2018, 3, e000303.	2.0	12
114	Preclinical and Clinical Characterization of Fibroblast-derived Neuregulin-1 on Trastuzumab and Pertuzumab Activity in HER2-positive Breast Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 5096-5108.	3.2	12
115	Use of Formalin-Fixed Paraffin-Embedded Samples for Gene Expression Studies in Breast Cancer Patients. <i>PLoS ONE</i> , 2015, 10, e0123194.	1.1	11
116	Follow-up results of NOAH, a randomized phase III trial evaluating neoadjuvant chemotherapy with trastuzumab (CT+H) followed by adjuvant H versus CT alone, in patients with HER2-positive locally advanced breast cancer.. <i>Journal of Clinical Oncology</i> , 2013, 31, 503-503.	0.8	10
117	Event-free survival analysis of the prospectively randomized phase III ETNA study with neoadjuvant nab-paclitaxel (nab-P) versus paclitaxel (P) followed by anthracycline regimens in women with HER2-negative high-risk breast cancer.. <i>Journal of Clinical Oncology</i> , 2019, 37, 515-515.	0.8	10
118	Accurate Data Processing Improves the Reliability of Affymetrix Gene Expression Profiles from FFPE Samples. <i>PLoS ONE</i> , 2014, 9, e86511.	1.1	10
119	Time to CA19-9 nadir: a clue for defining optimal treatment duration in patients with resectable pancreatic ductal adenocarcinoma. <i>Cancer Chemotherapy and Pharmacology</i> , 2020, 85, 641-650.	1.1	8
120	Predictive biomarkers of everolimus efficacy in HER2+ advanced breast cancer: Combined exploratory analysis from BOLERO-1 and BOLERO-3.. <i>Journal of Clinical Oncology</i> , 2015, 33, 512-512.	0.8	8
121	Modulation of the Estrogen/erbB2 Receptors Cross-talk by CDK4/6 Inhibition Triggers Sustained Senescence in Estrogen Receptor ⁺ and ErbB2-positive Breast Cancer. <i>Clinical Cancer Research</i> , 2022, 28, 2167-2179.	3.2	8
122	Trastuzumab re-treatment following adjuvant trastuzumab and the importance of distant disease-free interval: the HERA trial experience. <i>Breast Cancer Research and Treatment</i> , 2016, 155, 127-132.	1.1	7
123	Derived Neutrophil-to-Lymphocyte Ratio Predicts Pathological Complete Response to Neoadjuvant Chemotherapy in Breast Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 827625.	1.3	7
124	Role and evaluation of pathologic response in early breast cancer specimens after neoadjuvant therapy: consensus statement. <i>Tumori</i> , 2022, 108, 196-203.	0.6	6
125	Capecitabine/Cyclophosphamide/Methotrexate for Patients with Metastatic Breast Cancer: A Dose-Finding, Feasibility, and Efficacy Study. <i>Clinical Breast Cancer</i> , 2006, 7, 321-325.	1.1	5
126	A Phase I Study of Ixabepilone in Combination With Epirubicin in Patients With Metastatic Breast Cancer. <i>Clinical Breast Cancer</i> , 2012, 12, 167-174.	1.1	5

#	ARTICLE	IF	CITATIONS
127	Abstract LB-302: A comprehensive study of translational research and safety exploration of the vascular disrupting agent (VDA) AVE8062 in combination with cisplatin administered every 3 weeks to patients with advanced solid tumors. , 2008, , .		5
128	Cardiac safety in a phase II study of trastuzumab emtansine (T-DM1) following anthracycline-based chemotherapy as adjuvant or neoadjuvant therapy for early-stage HER2-positive breast cancer.. Journal of Clinical Oncology, 2012, 30, 532-532.	0.8	5
129	Never use anthracyclines with trastuzumab: it is time to reconsider the taboo. Breast Cancer Research and Treatment, 2009, 117, 599-601.	1.1	4
130	Ki67 during and after neoadjuvant trastuzumab, pertuzumab and palbociclib plus or minus fulvestrant in HER2 and ER-positive breast cancer: The NA-PHER2 Michelangelo study.. Journal of Clinical Oncology, 2019, 37, 527-527.	0.8	4
131	Four-drug sequential regimen in advanced breast cancer. Breast Cancer Research and Treatment, 1987, 10, 151-157.	1.1	3
132	Cisplatin and Cyclophosphamide in Advanced Ovarian Carcinoma. American Journal of Clinical Oncology: Cancer Clinical Trials, 1990, 13, 199-203.	0.6	3
133	Learning from CI-941 about pharmacokinetically guided dose escalation. European Journal of Cancer, 1992, 28, 1302-1304.	1.3	3
134	New active drugs in the treatment of lymphomas. Current Opinion in Oncology, 1994, 6, 480-488.	1.1	3
135	The cost of life: should it matter to doctors?. Annals of Oncology, 2006, 17, 357-358.	0.6	3
136	Is there room for another HER2-targeting drug?. Lancet Oncology, The, 2018, 19, 847-849.	5.1	3
137	The TRAR gene classifier to predict response to neoadjuvant therapy in HER2-â€positive and ER-â€positive breast cancer patients: an explorative analysis from the NeoSphere trial. Molecular Oncology, 2022, 16, 2355-2366.	2.1	3
138	Surrogate Markers for Targeted Therapy-Based Treatment Activity and Efficacy. Journal of the National Cancer Institute Monographs, 2011, 2011, 91-94.	0.9	2
139	Pathological complete response in breast cancer â€ Authors' reply. Lancet, The, 2015, 385, 114-115.	6.3	2
140	Proliferation-, estrogen-, and T-cell-related metagenes to predict outcome after adjuvant/neoadjuvant chemotherapy for operable breast cancer in the ECTO trial.. Journal of Clinical Oncology, 2013, 31, 1014-1014.	0.8	2
141	Reply to S.M. Ali et al. Journal of Clinical Oncology, 2009, 27, e274-e275.	0.8	1
142	HER2-Directed T-Cell Receptor-â€Mimicking Antibody: A â€Me Tooâ€or an Example of Novel Antitumor Aggressive Mimicry?. Journal of the National Cancer Institute, 2013, 105, 161-163.	3.0	1
143	BOLERO-3 results: pharmacological activity or pharmacokinetic effect? â€ Authors' reply. Lancet Oncology, The, 2014, 15, e304-e305.	5.1	1
144	Multidrug regimens for treatment of older patients with metastatic pancreatic cancer. Digestive and Liver Disease, 2021, 53, 117-121.	0.4	1

#	ARTICLE	IF	CITATIONS
145	State of the art of adjuvant therapy. European Journal of Cancer, Supplement, 2008, 6, 27-30.	2.2	0
146	Autoimmunity and Benefit from Trastuzumab Treatment in Breast Cancer: Results from the HERA Trial. Anticancer Research, 2019, 39, 797-802.	0.5	0
147	Pertuzumab â€“ a HER-2 Dimerisation Inhibitor â€“ for the Treatment of Breast and Other Cancers. , 2011, , 73-90.		0
148	Introduction and Background Biology. , 2013, , 1-12.		0
149	Freedom from progression (FFP) by adding paclitaxel (T) to doxorubicin (A) followed by CMF as adjuvant or primary systemic therapy: 10-yr results of a randomized phase III European Cooperative Trial in Operable Breast Cancer (ECTO).. Journal of Clinical Oncology, 2013, 31, 537-537.	0.8	0
150	An immune-related signature for prediction of risk of late recurrences beyond proliferation and ER-related genes in ER-positive breast cancer.. Journal of Clinical Oncology, 2014, 32, 530-530.	0.8	0
151	Strategies for clinical development of monoclonal antibodies beyond first-in-man trials: Tested doses and rationale for dose selection.. Journal of Clinical Oncology, 2015, 33, 3040-3040.	0.8	0
152	Introduction and background biology. , 2016, , 1-13.		0
153	Demethylating agents to upregulate HLAs and antigen presenting machinery (APM) related genes in HER2+ breast cancer (BC) cell lines.. Journal of Clinical Oncology, 2018, 36, e13012-e13012.	0.8	0
154	The GATTO study: A phase I of the anti-MUC1 Gatipotuzumab (GAT) in combination with the anti-EGFR Tomuzotuximab (TO) in patients with EGFR positive solid tumors.. Journal of Clinical Oncology, 2018, 36, TPS2596-TPS2596.	0.8	0